Dr. André Uddin
Andre Uddin is managing director, healthcare research at Mackie Research. Uddin has over 20 years of global experience in the investment, biotechnology and pharmaceutical industries, most recently as strategic advisor and consultant to a number of leading TSX and LSE companies. He was also Vice-President of Strategic Development for a NASDAQ-listed biopharmaceutical company. Uddin began his career in the brokerage community, where he was a top-ranked analyst specializing in coverage of the Canadian biotechnology, pharmaceutical and medical device sectors at National Bank Financial, Research Capital and Merrill Lynch Canada. Uddin holds an Honours Bachelor of Science in Biochemistry from the University of Toronto, and a Ph.D in Biological Chemistry from McGill University. Uddin's bio-organic research has been widely published in many scientific journals, including the Journal of American Chemical Society, Biochemistry and Nucleic Acid Research.
Recent Articles
Target Price Boosted on Canadian Pharma Co. 11/30/2022
This company, undergoing a business model shift, is doing well and remains Buy rated despite a weaker-than-expected Q3/22, noted a Research Capital Corp. report.
Life Sciences Co. Exceeds Expectations in Q3/22 11/22/2022
During the quarter, the Canadian specialty biopharma performed well and maintained a healthy balance sheet, such that it raised revenue guidance for this year, noted a Research Capital Corp. report.
Pharma Co. Won't See Bump in Sales From New COVID Drug 11/18/2022
The U.S. Food and Drug Administration Advisory Panel denied the approval of this therapeutic for patients hospitalized with severe SARS-CoV-2, yet it is still a Buy, noted a Research Capital Corp. report.
Medical Device Co.'s Q2/22 Results Better Than Expected 11/09/2022
Along with improving its numbers during the quarter, this firm sold its first ultrasound ablation machines in North America, noted a Research Capital Corp. report.
Recent Quotes
"Positive Phase 2a data were achieved with AGN's ifenprodil."
—
Dr. André Uddin, Research Capital Corporation
(11/30/22)
more >
"It would be logical for AGN to develop ifenprodil for two indications."
—
Dr. André Uddin, Research Capital Corporation
(7/28/22)
more >
"In the Phase 2a trial in IPF, AGN's ifenprodil hit its endpoint."
—
Dr. André Uddin, Research Capital Corporation
(7/18/22)
more >
"AGN's current valuation is favorable from a risk-reward standpoint."
—
Dr. André Uddin, Research Capital Corporation
(1/28/22)
more >
"AGN's risk/reward profile is attractive."
—
Dr. André Uddin, Research Capital Corporation
(12/6/21)
more >
"AGN is switching focus to the IPF/chronic cough indication."
—
Dr. André Uddin, Research Capital Corporation
(8/4/21)
more >
"AGN requested a meeting with the FDA to discuss advancing ifenprodil."
—
Dr. André Uddin, Research Capital Corporation
(5/10/21)
more >
"Final results from AGN's Phase 2b COVID-19 trial are expected soon."
—
Dr. André Uddin, Research Capital Corporation
(3/1/21)
more >
